$MRNA, $GMAB, $BNTX, $BGNE, $LEGN, $ALNY all dropped by over 10% in the past week.
Stocks in the biotechnology group experienced a more pronounced decline last week, with an average drop of around 10%. Our recommendations were to sell or initiate short positions. You can check signals for these stocks in the following bot: Swing-Trader-High-Volatility-Stocks-for-Active-Trading-TA-FA
Group Biotechnology Highlights: Market Cap The average market capitalization across the group is $25.3 billion. Market caps for tickers in the group range from $13 billion to $41.2 billion. MRNA holds the highest valuation in this group at $41.2 billion, while the lowest valued company is LEGN at $13 billion.
High and Low Price Notable News The average weekly price growth across all stocks in the group was -9.69%. For the same group, the average monthly price growth was -4.47%, and the average quarterly price growth was -11.7%. ALNY experienced the highest price growth at -5.69%, while MRNA experienced the largest decline at -13.99%.
- 7/28/23 4:21 PM: Moderna (MRNA, $118.51) was a top loser this week, declining by -5.02%.
- 6/14/23 8:29 AM: BioNTech SE American Depositary Share (BNTX, $115.6) was a top weekly gainer, with a +5.23% increase.
- 5/25/23 7:44 AM: Legend Biotech (LEGN, $66.04) was a top loser this week, declining by -7.44%.
Volume The average weekly volume growth across all stocks in the group was 3.83%. For the same stocks in the group, the average monthly volume growth was 9.48%, and the average quarterly volume growth was 2.28%.
Fundamental Analysis Ratings The average fundamental analysis ratings, with 1 being the best and 100 being the worst, are as follows:
- Valuation Rating: 64
- P/E Growth Rating: 73
- Price Growth Rating: 64
- SMR Rating: 68
- Profit Risk Rating: 72
- Seasonality Score: 2 (-100 ... +100)
Notable Companies The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), and Nektar Therapeutics (NASDAQ:NKTR).
Industry Description Biotechnology involves genetic or protein engineering to produce medicines and therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry heavily focuses on research and development, striving to come up with cutting-edge solutions for health. Opportunities for growth arise from new discoveries for disease treatment. However, these discoveries must obtain regulatory approval from the U.S. Food and Drug Administration (FDA) before reaching the markets. Companies like Amgen Inc., Gilead Sciences, Inc., and Celgene Corporation exemplify the industry.
Industry Market Cap The average market capitalization across the Biotechnology Industry is $2.1 billion. Market caps for tickers in the industry range from $402 million to $361.8 billion. NONOF holds the highest valuation in this group at $361.8 billion, while the lowest valued company is PNEXF at $402 million.
Industry High and Low Price Notable News The average weekly price growth across all stocks in the Biotechnology Industry was -4.22%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was 10.93%. VTGN experienced the highest price growth at 617.03%, while ARAV experienced the largest decline at -82.26%.
- 7/28/23 4:21 PM: Moderna (MRNA, $118.51) was a top loser this week, declining by -5.02%.
- 6/14/23 8:29 AM: BioNTech SE American Depositary Share (BNTX, $115.6) was a top weekly gainer, with a +5.23% increase.
- 5/25/23 7:44 AM: Legend Biotech (LEGN, $66.04) was a top loser this week, declining by -7.44%.
Volume in the Industry The average weekly volume growth across all stocks in the Biotechnology Industry was -3.14%. For the same stocks in the industry, the average monthly volume growth was -24.5%, and the average quarterly volume growth was -0.24%.
Fundamental Analysis Ratings for the Industry The average fundamental analysis ratings, with 1 being the best and 100 being the worst, are as follows:
- Valuation Rating: 50
- P/E Growth Rating: 87
- Price Growth Rating: 65
- SMR Rating: 93
- Profit Risk Rating: 95
- Seasonality Score: 0 (-100 ... +100)
MRNA's Stochastic Oscillator has remained in the oversold zone for 7 days. The extended duration in the oversold zone suggests that the price of this ticker is likely to rebound soon, as an extended stay in the oversold zone often signals a more imminent uptrend.
Stock Forecast, Price, News, Quote: The current price of $101.20 has crossed the resistance line at $175.56 and is currently trading between the $175.56 resistance and the $69.57 support lines. Over the period of 07/05/23 - 08/04/23, the price experienced a -12% downtrend. During the week of 07/28/23 - 08/04/23, the stock fell by -9%.
Aroon Indicator for GMAB shows a potential upward move: GMAB's Aroon Indicator signaled a bullish trend on August 04, 2023. Tickeron's A.I. advisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the AroonUp indicator rises above 70 and the AroonDown indicator remains below 30, it suggests that the stock could be primed for a bullish move. Traders might consider buying the stock or exploring call options. A.I. advisor analyzed 323 similar instances where the Aroon Indicator displayed a similar pattern. In 242 out of 323 cases, the stock moved higher in the days following the signal. This indicates a 75% chance of a higher price movement.
Stock Forecast, Price, News, Quote: The current price of $37.60 has breached the resistance line at $40.41 and is currently trading between the $40.41 resistance and the $34.02 support lines. Over the period of 07/05/23 - 08/04/23, the price experienced a -3% downtrend. During the week of 07/28/23 - 08/04/23, the stock fell by -11%. BNTX is in an upward trend: its price may rebound because it broke its lower Bollinger Band on July 26, 2023. BNTX may climb back above the lower band and trend towards the middle band. Traders could consider purchasing the stock or exploring call options. In 24 out of 26 instances where BNTX's price breached its lower Bollinger Band, its price further increased in the following month. The probability of a continued upward trend stands at 90%.
Stock Forecast, Price, News, Quote: The current price of $98.50 has surpassed the resistance line at $153.18 and is currently trading between the $153.18 resistance and the $81.33 support lines. Over the period of 07/05/23 - 08/04/23, the price experienced a -2% downtrend. During the week of 07/28/23 - 08/04/23, the stock fell by -0.88%. BGNE's 50-day moving average has crossed bearishly below its 200-day moving average on July 17, 2023. This development could signal a long-term bearish trend for the stock as it shifts to a downward trajectory.
Stock Forecast, Price, News, Quote: The current price of $187.52 is below the lowest resistance line found by A.I. at $239.67. Over the period of 07/05/23 - 08/04/23, the price experienced a +6% uptrend, while the week of 07/28/23 - 08/04/23 reflects a -10% downtrend.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
MRNA's RSI Oscillator recovers from overbought zone
The 10-day RSI Oscillator for MRNA moved out of overbought territory on August 26, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In 22 of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on MRNA as a result. In 66 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The 10-day moving average for MRNA crossed bullishly above the 50-day moving average on August 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +9.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 213 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.099) is normal, around the industry mean (25.951). P/E Ratio (26.455) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (436.793).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology
Advertisement